Column Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Column Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-522	Closed	-$71.9K	–	840
2023 Q1	$71.9K	Sell	522 -713	-58%	-$92.5K	0.01%	270
2022 Q4	$160K	Sell	1,235 -287	-19%	-$33.3K	0.03%	146
2022 Q3	$168K	Sell	1,522 -433	-22%	-$43.6K	0.03%	137
2022 Q2	$147K	Sell	1,955 -908	-32%	-$66.8K	0.03%	143
2022 Q1	$224K	Hold	2,863	–	–	0.04%	125
2021 Q4	$258K	Sell	2,863 -98	-3%	-$8.38K	0.05%	109
2021 Q3	$274K	Sell	2,961 -71	-2%	-$5.47K	0.06%	101
2021 Q2	$236K	Buy	3,032 +1,403	+86%	+$106K	0.05%	111
2021 Q1	$121K	Buy	1,629 +1,091	+203%	+$101K	0.03%	160
2020 Q4	$92K	Sell	538 -463	-46%	-$68.6K	0.02%	179
2020 Q3	$141K	Hold	1,001	–	–	0.04%	121
2020 Q2	$160K	Hold	1,001	–	–	0.05%	106
2020 Q1	$98K	Sell	1,001 -35	-3%	-$4K	0.04%	126
2019 Q4	$133K	Buy	+1,036	New	+$105K	0.07%	116

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Capital Advisors's SRPT Position: Q2 2023 in Review

Column Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 522 shares — an estimated $71.9K sold.

Column Capital Advisors first reported a position in SRPT in Q4 2019 and held it in 14 quarters. The position peaked at $274K in Q3 2021. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Column Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Column Capital Advisors sold 522 Sarepta Therapeutics shares in Q2 2023, an estimated $71.9K.
Column Capital Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 14 quarters.
Column Capital Advisors's Sarepta Therapeutics position peaked at $274K in Q3 2021.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Column Capital Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.